Combined mucoactive therapy of diseases of the respiratory system associated with formation of a viscous secretion in children

S.P. Kryvopustov


The article considers in detail the mechanisms of therapeutic action of various mucoactive agents. Modern approaches to mucoactive therapy of respiratory diseases in children are presented, they are accompanied by the formation of a viscous secretion. At the same time, the expediency of combined use of drugs having different mechanism of mucoactive action — ambroxol and carbocysteine is justified. In addition, it helps to increase the effectiveness of antibiotic therapy for respiratory diseases.


ambroxol; children; respiratory diseases; carbocysteine


Abaturov AYe. Mucolytic therapy of inflammatory diseases of tracheobronchila system in children. Medicus amicus. 2006;1. (in Russian).

Volkov IK. Role of mucolytic therapy in treatment of chronic pulmonary diseases in children. Consilium medicum. Supplemen. 2005;1. (in Russian).

Zaitseva OV. Mucolytic therapy in comprehensive treatment of pulmonary diseases in children. Consilium medicum. Pediatrics. 2002;5(10). (in Russian).

Zaitseva OV. Mucolytic agents for the treatment of pulmonary diseases in children: current approaches to the problem. Rossijskij medicinskij zhurnal. 2003;1. (in Russian).

Prescribing information for Pektolvan®C.

Kostromina VP, Yaroschuk LB. Rational mucolytic therapy in the treatment of pulmonary diseases. Therapia. 2006;3:26-32. (in Russian).

Maev IV, Busarova GA. Mucolytic agents for the treatment of chronic obstructive lung disease. Lechashhij vrach. 2003;1. (in Russian).

Marushko YuV, Gischak TV, Mika My, Marushko YeYu. Experience of Pektolvan C usage for the complex therapy of broncho-pulmonary diseases in children. Zdorov’ja Ukrainy. December 2015. (in Ukrainian).

Mizernitskyi YuL, author; CaregorodcevAD, Tabolin VA, editors. Otharkivajushhie i mukoliticheskie sredstva v terapii bronholegochnyh zabolevanij u detej. In: Rukovodstvo po farmakoterapii v pediatrii i detskoj hirurgii [Expectorants and mucolytic agents for the therapy of broncho-pulmonary diseases in children. In: Guidelines on pharmacotherapy in pediatrics and pediatric surgery]. Moscow: Medpraktika-M; 2002. (in Russian).

Paramonova NS, Kharchenko OF. Klinicheskaja farmakologija [Clinical pharmacology]. Minsk: Vysshaja shkola; 2012. (in Russian). 320p.

Chuchalin AG, editor. Respiratornaja medicina: rukovodstvo [Respiratory medicine: guidelines]. Vol. 1. Moscow: Geotar-Media; 2007. 2 vols. (in Russian).

Sinopalnikov AI, Kliachkina IL. Place of mucolytic agents in complex treatment of pulmonary diseases. Rossijskij medicinskij vestnik. 1997;2(4). (in Russian).

Chuchalin AG, Abrosimov VN. Kashel [Cough]. 2nd ed., rev. Moscow: Chelovek i lekarstvo; 2012. 160p.

Beeh KM, Beier J, Esperester A, Paul LD. Antiinflammatory properties of ambroxol. Eur J Med Res. 2008 Dec 3;13(12):557-62. PMID: 19073395.

Duijvestijn YC, Mourdi N, Smucny J, et al. Acetylcysteine and carbocysteine for acute upper and lower respiratory tract infections in paediatric patients without chronic broncho-pulmonary disease. Cochrane Database Syst Rev. 2009 Jan 21;1. doi: 10.1002/14651858.CD003124.pub3.

Franchini F, et al. Effect of a mucolytic agent on the bioavailability of antibiotics in patients with chronic respiratory disease. Current Therapeutic Research. 1988;43(4).

Klossek JM, Mesbah K. Presentation and treatment of acute maxillary sinusitis in general practice: a French observational study. Rhinology. 2011;49(1):84-9. doi: 10.4193/Rhino09.126.

Ndour C, Ahmed K, Nakagawa T, et al. Modulating effects of mucoregulating drugs on the attachment of Haemophilus influenzae. Microb. Pathog. 2001;30(3):121-7. doi: 10.1006/mpat.2000.0417.

Nogawa H, Ishibashi Y, Ogawa A, et al. Carbocysteine can scavenge reactive oxygen species in vitro. Respirology. 2009; Jan 14(1):53-9. doi: 10.1111/j.1440-1843.2008.01424.x.

Seagrave J, Albrecht HH, Hill DB, Rogers DF, Solomon G. Effects of guaifenesin, N-acetylcysteine, and ambroxol on MUC5AC and mucociliary transport in primary differentiated human tracheal-bronchial cells. Respir Res. 2012 Oct 31;13:98. doi: 10.1186/1465-9921-13-98.

Wang DY, Wardani RS, Singh K, Thanaviratananich S, Vicente G, Xu G, et al. A survey on the management of acute rhinosinusitis among Asian physicians. Rhinology. 2011 Sep;49(3). doi: 10.4193/Rhino10.169.

Yang B, Yao DF, Ohuchi M, et al. Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels. EurRespir J. 2002;19(5):952-8. PMID: 12030738.

Copyright (c) 2017 CHILD`S HEALTH

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2020


   Seo анализ сайта